These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37729740)

  • 1. Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency.
    Xiang J; Liu X; Hao Y; Zhu Y; Wu M; Lou J; Wang Y; Xu C; Xie Y; Huang J
    Transl Oncol; 2023 Dec; 38():101787. PubMed ID: 37729740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
    Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
    Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor-associated adrenal insufficiency in Chinese cancer patients: a retrospective analysis.
    Cai Q; Wu W; Li X; Xu Q; Zhao L; Lv Q
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):14113-14123. PubMed ID: 37553420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-Related Adverse Event-Related Adrenal Insufficiency Mediates Immune Checkpoint Inhibitors Efficacy in Cancer Treatment.
    Zhang S; Wu J; Zhao Y; Zhang J; Zhang X; Wu C; Zhang Z; Guo Z
    Cancer Manag Res; 2024; 16():151-161. PubMed ID: 38501053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and outcomes of patients with primary liver cancer and immune checkpoint inhibitor-associated adrenal insufficiency: A retrospective cohort study.
    Cai Q; Wu W; Li R; Li X; Xu Q; Zhao L; Lv Q
    Int Immunopharmacol; 2024 Jan; 127():111337. PubMed ID: 38064811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.
    Cui K; Wang Z; Zhang Q; Zhang X
    Ann Transl Med; 2022 Mar; 10(5):251. PubMed ID: 35402601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.
    Martella S; Lucas M; Porcu M; Perra L; Denaro N; Pretta A; Deias G; Willard-Gallo K; Parra HS; Saba L; Scartozzi M; Wekking D; Kok M; Aiello MM; Solinas C
    Semin Oncol; 2023 Dec; 50(6):144-148. PubMed ID: 38151399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.
    Kurokawa K; Mitsuishi Y; Shimada N; Ito N; Ogiwara M; Miura K; Asao T; Ko R; Shukuya T; Shibayama R; Goto H; Takahashi K
    Thorac Cancer; 2023 Feb; 14(5):442-449. PubMed ID: 36523162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer.
    Ida H; Goto Y; Sato J; Kanda S; Shinno Y; Morita R; Murakami S; Matsumoto Y; Yoshida T; Horinouchi H; Fujiwara Y; Yamamoto N; Fukuda T; Ohashi K; Ohe Y
    Med Oncol; 2020 Mar; 37(4):30. PubMed ID: 32180046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
    Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
    Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
    Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
    Nebhan CA; Cortellini A; Ma W; Ganta T; Song H; Ye F; Irlmeier R; Debnath N; Saeed A; Radford M; Alahmadi A; Diamond A; Hoimes C; Ramaiya N; Presley CJ; Owen DH; Abou Alaiwi S; Nassar A; Ricciuti B; Lamberti G; Bersanelli M; Casartelli C; Buti S; Marchetti P; Giusti R; Filetti M; Vanella V; Mallardo D; Macherla S; Sussman TA; Botticelli A; Galetta D; Catino A; Pizzutilo P; Genova C; Dal Bello MG; Kalofonou F; Daniels E; Ascierto PA; Pinato DJ; Choueiri TK; Johnson DB; Marron TU; Wang Y; Naqash AR
    JAMA Oncol; 2021 Dec; 7(12):1856-1861. PubMed ID: 34734989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
    Manaka K; Sato J; Takeuchi M; Watanabe K; Kage H; Kawai T; Sato Y; Miyagawa T; Yamada D; Kume H; Sato S; Nagase T; Iiri T; Nangaku M; Makita N
    Sci Rep; 2021 Jun; 11(1):11617. PubMed ID: 34078988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
    Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
    J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.